

Please type a plus sign (+) inside this box → [+]

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO


# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## COMPLETE IF KNOWN

Application Number	09/618,235
Confirmation Number	8554
Filing Date	7/18/2000
First Named Inventor	D N. Rubingh
Group Art Unit	1652
Examiner Name	W. W. Moore
Attorney Docket Number	7670

SHEET 1 of 2



## U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	U.S. PATENT DOCUMENT Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
WWM	01	5,766,898	A	Loeburg	06/16/1998	
WWM	02	5,972,339	A	Walker	10/26/1999	
WWM	03	5,985,264	A	Metzger et al.	11/16/1999	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENT Office <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
WWM	04	EP	0 130 756	A1	Genetech, Inc.	01/09/1985	
	05	EP	0 260 105	B1	Genencor, Inc.	03/16/1988	
	06	EP	0 398 539	B1	Amgen Inc.	11/22/1990	
	07	WO	87/05050	A1	Genex Corp.	08/27/1987	
	08	WO	88/07578	A1	Genentech, Inc.	10/06/1988	
	09	WO	88/08028	A1	Genex Corp.	10/20/1988	
	10	WO	88/08164	A1	Genex Corp.	10/20/1988	
	11	WO	93/25667	A1	Scripps Research	12/23/1993	
	12	WO	95/07991	A2	Procter & Gamble	03/23/1995	
	13	WO	95/20039	A2	Carlsberg A/S	07/27/1995	
	14	WO	99/33868	A2	Smith Kline Beech.	07/08/1999	
	15	WO	99/40936	A2	Amer. Cyanamid	08/19/1999	
	16	WO	99/41369	A2	Maxygen, Inc.	08/19/1999	
	17	WO	99/42097	A1	Dovetail Tech., Inc.	08/26/1999	
	18	WO	99/44635	A1	Med. College of OH	09/10/1999	
	19	WO	99/45904	A1	Allergenic Inc.	09/16/1999	
WWM	20	WO	00/09707	A1	Genencor Int'l., Inc.	02/24/2000	

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>6</sup>
WWM	21	Atassi, M.Z., et al., "Structure, Activity, and Immune (T and B Cell) Recognition of Botulinum Neurotoxins", <b>Critical Reviews in Immunology</b> , Vol. 19, pp. 219-260 (1999)	
	22	Blaser, K., "Allergen Dose Dependent Cytokine Production Regulates Specific IgE and IgG Antibody Production", <b>New Horizons In Allergy Immunotherapy</b> , Sehon et al. (Ed.) Plenum Press, N.Y. (1996)	
	23	Cui, J., et al., "Inhibition of T Helper Cell Type 2 Cell Differentiation and Immunoglobulin E Response by Ligand-activated Vα14 Natural Killer T Cells", <b>J. Exp. Med.</b> , Vol. 190, No. 6, pp. 783-792, (9/20/1999)	
	24	Deml, L., et al., "Immunostimulatory CpG Motifs Trigger a T Helper-1 Immune Response to Human Immunodeficiency Virus Type-1 (HIV-1) gp 160 Envelope Proteins", <b>Clin Chem Lab Med</b> , Vol. 37, No. 3, pp. 199-204 (1999)	
	25	Ferru, I., et al., "Comparison of the Immune Response Elicited by a Free Peptide and a Lipopeptide Construct", <b>Peptide Research</b> , Vol. 9, No. 3, pp. 136-143 (1996)	
WWM	26	Haack, T., et al., "D-Amino Acids in Protein De Novo Design. II. Protein-diastereomerism Versus Protein-enantiomerism", <b>Letters in Peptide Science</b> , Vol. 4, pp. 377-386 (1997)	

Please type a plus sign (+) inside this box → [ + ]

PTO/SB08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 2 of 2



## COMPLETE IF KNOWN

Application Number	09/618,235
Confirmation Number	8554
Filing Date	7/18/2000
First Named Inventor	D N. Rubingh
Group Art Unit	1652
Examiner Name	W. W. Moore
Attorney Docket Number	7670

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS (continued)

EXAMINER INITIALS*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
WMM	27	Herve, M., et al., "On the Immunogenic Properties of Retro-Inverso Peptides. Total Retro-Inversion of T-Cell Epitopes Causes a Loss of Binding to MHC II Molecules", <i>Molecular Immunology</i> , Vol. 34, No. 2, pp. 157-163 (1997)	
	28	Hoyne, G. F., et al., "Peptide-Mediated Regulation of the Allergic Immune Response", <i>Immunology and Cell Biology</i> , Vol. 74, pp. 180-186 (1996)	
	29	Ikagawa, S., MD., et al., "Single Amino Acid Substitutions on a Japanese Cedar Pollen Allergen (Cry j 1)-derived Peptide Induced Alterations in Human T Cell Responses and T Cell Receptor Antagonism", <i>J. Allergy Clin. Immuno.</i> , Vol. 97, No. 1, Part 1, pp. 53-64 (Jan 1996)	
	30	Lofthouse, S. A., et al., "Induction of T <sub>2</sub> (cytotoxic lymphocyte) and/or T <sub>1</sub> (antibody) Responses to a Mucin-1 tumour Antigen", <i>Vaccine</i> , Vol. 15, No. 14, pp. 1586-1593 (1997)	
	31	Maillere, B., et al., "Probing Immunogenicity of a T-Cell Epitope by L-Alanine and D-Amino Acid Scanning", <i>Molecular Immunology</i> , Vol. 32, No. 14/15, pp. 1073-1080 (1995)	
	32	McKee, H. J., et al., "T Cell Cytokine Responses to Cartilage Aggrecan in BALB/c Mice", <i>Biochemical Society Transactions</i> , Vol. 25, p 311S (1997)	
	33	Moore, A., et al., "The Adjuvant Combination Monophosphoryl Lipid A and QS21 Switches T Cell Responses Induced With a Soluble Recombinant HIV Protein from Th2 and Th1", <i>Vaccine</i> , Vol. 17, pp. 2517-2527 (1999)	
	34	Rosenthal, K. S., et al., "Immunization with a LEAPS™ Heteroconjugate Containing a CTL Epitope and a Peptide from Beta-2-microglobulin Elicits a Protective and DTH Response to Herpes Simplex Virus Type 1", <i>Vaccine</i> , Vol. 17, pp. 535-542 (1999)	
	35	Sinha, P., et al., "A Minimized Fc Binding Peptide from Protein A Induces Immunocyte Proliferation and Evokes Th1-Type Response in Mice", <i>Biochemical and Biophysical Research Communications</i> , Vol. 258, pp. 141-147 (1999)	
	36	Specht, C., et al., "The Murine (H-2 <sup>k</sup> ) T-Cell Epitopes of Bee Venom Phospholipase A <sub>2</sub> Lie Outside the Active Site of the Enzyme", <i>Int Arch Allergy Immunol</i> , Vol. 112, pp. 226-230 (1997)	
↓	37	Wiedermann, U., et al., "Effects of Adjuvants on the Immune Response to Allergens in a Murine Model of Allergen Inhalation: Cholera Toxin Induces a Th1-like Response to Bet V 1, the Major Birch Pollen Allergen", <i>Clin Exp Immunol</i> , Vol. 111, pp. 144-151 (1998)	
WMM	38	Zimmerman, D. H., et al., "Immunization with Peptide Heteroconjugates Primes a T Helper Cell Type 1-Associated Antibody (IgG2a) Response that Recognizes the Native Epitope on the 38-kDa Protein of <i>Mycobacterium tuberculosis</i> ", <i>Vaccine Research</i> , Vol. 5, No. 2, pp. 103-118 (1996)	
EXAMINER		DATE CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, D.C. 20231.